
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : YB002
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
YouthBio Gets FDA INTERACT Feedback on YB002 Alzheimer’s Gene Therapy
Details : YB002 is a first-in-class gene therapy designed to safely and transiently express Yamanaka factors in the brain. It is being evaluated for the treatment of alzheimer's disease.
Product Name : YB002
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
September 25, 2025
Lead Product(s) : YB002
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
